BidaskClub upgraded shares of Strongbridge Biopharma (NASDAQ:SBBP) from a hold rating to a buy rating in a research note released on Wednesday.
Several other equities research analysts have also recently commented on SBBP. Zacks Investment Research cut shares of Strongbridge Biopharma from a hold rating to a sell rating in a research report on Thursday, September 28th. ValuEngine cut shares of Strongbridge Biopharma from a hold rating to a sell rating in a research report on Monday, October 2nd. HC Wainwright reiterated a buy rating and set a $18.00 price target on shares of Strongbridge Biopharma in a research report on Wednesday, November 15th. Finally, Cantor Fitzgerald started coverage on shares of Strongbridge Biopharma in a research report on Tuesday, December 5th. They set a buy rating and a $14.00 price target for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $12.25.
Shares of Strongbridge Biopharma (NASDAQ SBBP) opened at $6.75 on Wednesday. Strongbridge Biopharma has a 1 year low of $2.00 and a 1 year high of $8.85. The company has a debt-to-equity ratio of -1.89, a quick ratio of 4.61 and a current ratio of 4.70. The company has a market cap of $268.73 and a P/E ratio of -2.00.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.